Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhe Wang has a total of 416 co-authors. Here are the top co-authors by number of shared publications:

  • Yixiong Liu

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University (Air Force Medical University), Xi'an, China

    18 shared publications
  • Yingmei Wang

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, School of Basic Medicine and Xijing Hospital, Fourth Military Medical University, Xi'an, China

    16 shared publications
  • Danhui Zhao

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University (Air Force Medical University), Xi'an, China

    15 shared publications
  • Linni Fan

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, School of Basic Medicine and Xijing Hospital. Fourth Military Medical University, Xi'an, China

    14 shared publications
  • Qingguo Yan

    State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Air Force Medical University, Xi'an, China

    13 shared publications
  • Shuangping Guo

    State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Air Force Medical University, Xi'an, China

    12 shared publications

Latest Publications

  • Open Access

    SLC45A4-mediated putrescine uptake functionally modulates HOXA1 and promotes bortezomib resistance in multiple myeloma

    by Jun Xu, Peng Shu, Liang Zhang, Huihui Li, Zhouyi Xu, Bo Meng, Julei Ma, Wei Wang, Wenjuan Wang, Xiaobing Wu, et al.

    Background: Bortezomib resistance remains a major barrier to durable responses in multiple myeloma, but how metabolic adaptation within the bone marrow niche sustains this phenotype remains incompletely understood. Methods: We integrated metabolomic profiling, isotope tracing, bulk RNA sequencing, single-cell RNA sequencing, co-culture tracing, molecular perturbation assays, protein–metabolite binding analyses, and pharmacological screening to investigate the role of SLC45A4-mediated putrescine uptake in bortezomib resistance. Results: Bortezomib-resistant myeloma cells preferentially accumulated putrescine through enhanced uptake rather than de novo polyamine biosynthesis. SLC45A4 was upregulated in resistant CD138⁺ myeloma cells and promoted putrescine import and bortezomib resistance. Mechanistically, SLC45A4-mediated putrescine accumulation was accompanied by increased HOXA1 recovery in putrescine-associated fractions and enhanced HOXA1-associated NF-κB signaling. Single-cell and co-culture tracing analyses further suggested that MDSCs in the bone marrow niche serve as a source of putrescine acquired by myeloma cells. Pharmacological suppression of this axis by abiraterone acetate, alone or combined with the HOX/PBX inhibitor HXR9, attenuated the resistance-associated phenotype. Conclusions: These findings identify an MDSC-supported SLC45A4–putrescine–HOXA1–NF-κB axis as a metabolic mechanism contributing to bortezomib resistance in multiple myeloma and nominate niche-dependent metabolic crosstalk as a potential therapeutic vulnerability.

  • PathFound: An agentic multimodal model activating evidence-seeking pathological diagnosis

    by Shengyi Hua, Jianfeng Wu, Tianle Shen, Kangzhe Hu, Zhongzhen Huang, Shujuan Ni, Zhihong Zhang, Yuan Li, Zhe Wang, Xiaofan Zhang


  • Open Access

    GloPath: An Entity‐Centric Foundation Model for Glomerular Lesion Assessment and Clinicopathological Insights

    by Qiming He, Jing Li, Tian Guan, Yifei Ma, Zimo Zhao, Yanxia Wang, Hongjing Chen, Yingming Xu, Shuang Ge, Yexing Zhang, et al.

    Glomerular pathology is central to the diagnosis and prognosis of renal diseases, yet the heterogeneity of glomerular morphology and fine‐grained lesion patterns remain challenging for current AI approaches. We present GloPath , an entity‐centric foundation model trained on over one million glomeruli extracted from 14 049 renal biopsy specimens using multi‐scale and multi‐view self‐supervised learning. GloPath addresses two major challenges in nephropathology: glomerular lesion assessment and clinicopathological insights discovery. For lesion assessment, GloPath was benchmarked across three independent cohorts on 52 tasks—including lesion recognition, grading, few‐shot classification, and cross‐modality diagnosis—outperforming state‐of‐the‐art methods in 42 tasks (80.8%). In the large‐scale real‐world study, it achieved an ROC‐AUC of 91.51% for lesion recognition, demonstrating strong robustness in routine clinical settings. For clinicopathological insights, GloPath systematically revealed statistically significant associations between glomerular morphological parameters and clinical indicators across 224 morphology–clinical variable pairs, demonstrating its capacity to connect tissue‐level pathology with patient‐level outcomes. Together, these results position GloPath as a scalable and interpretable platform for glomerular lesion assessment and clinicopathological discovery, representing a step toward clinically translatable AI in renal pathology.


  • Cross-staining pathological diagnosis based on spatially enriched multiple instance learning with clinical embedding

    by Qiming He, Shuang Ge, Qiang Huang, Jing Li, Tian Guan, Zhe Wang, Yonghong He

  • Open Access

    PathFound: An Agentic Multimodal Model Activating Evidence-seeking Pathological Diagnosis

    by Shengyi Hua, Jianfeng Wu, Tianle Shen, Kangzhe Hu, Zhongzhen Huang, Shujuan Ni, Zhihong Zhang, Yuan Li, Zhe Wang, Xiaofan Zhang

    Recent pathological foundation models have substantially advanced visual representation learning and multimodal interaction. However, most models still rely on a static inference paradigm in which whole-slide images are processed once to produce predictions, without reassessment or targeted evidence acquisition under ambiguous diagnoses. This contrasts with clinical diagnostic workflows that refine hypotheses through repeated slide observations and further examination requests. We propose PathFound, an agentic multimodal model designed to support evidence-seeking inference in pathological diagnosis. PathFound integrates the power of pathological visual foundation models, vision-language models, and reasoning models trained with reinforcement learning to perform proactive information acquisition and diagnosis refinement by progressing through the initial diagnosis, evidence-seeking, and final decision stages. Across several large multimodal models, adopting this strategy consistently improves diagnostic accuracy, indicating the effectiveness of evidence-seeking workflows in computational pathology. Among these models, PathFound achieves state-of-the-art diagnostic performance across diverse clinical scenarios and demonstrates strong potential to discover subtle details, such as nuclear features and local invasions.

  • Open Access

    PathOrchestra: a comprehensive foundation model for computational pathology with over 100 diverse clinical-grade tasks

    by Fang Yan, Jianfeng Wu, Jiawen Li, Wei Wang, Yirong Chen, Linda Wei, Jiaxuan Lu, Wen Chen, Zizhao Gao, Jianan Li, et al.

    The complexity and variability of high-resolution pathological images present significant challenges in computational pathology. While AI-driven pathology foundation models have advanced the field, they require large-scale datasets, substantial storage, and significant computational resources, as well as rigorous validation for clinical applicability. We present PathOrchestra, a versatile pathology foundation model trained on 287,424 slides from 21 tissue types across three centers. Evaluated on 112 tasks from 61 private and 51 public datasets, covering digital slide preprocessing, pan-cancer classification, lesion identification, multi-cancer subtype classification, biomarker assessment, gene expression prediction, and structured report generation. Across 27,755 whole slide images and 9,415,729 region-of-interest images, it achieved over 0.950 accuracy in 47 tasks, including pan-cancer classification, lymphoma subtyping, and bladder cancer screening. It is the first to generate structured reports for colorectal cancer and lymphoma. Overall, PathOrchestra demonstrates the clinical readiness of large-scale self-supervised pathology foundation models, achieving high accuracy and offering potential to digital medicine integration.


  • Primary pulmonary spindle cell sarcoma with novel MBNL2::NUTM1 fusion and associated langerhans cell hyperplasia

    by Jianfeng Wu, Mingyang Li, Danhui Zhao, Yixiong Liu, Wanni Xu, Lu Wang, Zhenyu Ke, Zhe Wang

  • Open Access

    FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α

    by Jun Xu, Xiaoyu Yang, Peng Shu, Wei Wang, Haibo Wu, Zhe Wang

    Triple-negative breast cancer (TNBC), particularly in patients with metastasis, is associated with limited treatment options and shorter survival times. In this study, through library screening and animal experiments, we identified that the low expression of FERM domain-containing protein 8 (FRMD8) in breast cancer type 1 susceptibility protein (BRCA1)-mutant breast cancer cells (TNBC subtype), significantly enhances the metastatic potential of tumor cells to various organs. Further functional experiments revealed that FRMD8low inhibited the cleavage of tmTNF-α (transmembrane TNF-α) and promoted the expression of surface tmTNF-α. We also identified that the mechanism by which FRMD8 regulates tmTNF-α is related to the inhibition of inactive rhomboid protein 2 (iRHOM2) degradation, which acts mainly through the endocytic pathway. Furthermore, FRMD8low/iRHOM2low greatly facilitated the in vivo metastasis of TNBC. Finally, we found that combined treatment with paclitaxel and etanercept reversed the expression of FRMD8 and iRHOM2, concomitantly inhibiting the metastatic potential in vivo. This study explores how FRMD8 influences TNF-α processing and the metastatic behavior of breast cancer, providing insights into molecular dynamics that could guide future therapeutic strategies to improve outcomes in patients with breast cancer.


  • Open Access

    Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer

    by Huan He, Manzhan Zhang, Xiaoxiao Yang, Shuai He, Xiayu Shi, Feng Hu, Chang Liu, Xingsen Zhang, Na Chen, Xiaoqian Zhu, et al.

    Drug metabolism liabilities are a major bottleneck in drug development, necessitating accurate metabolite prediction tools. While AI-driven methods have advanced, challenges remain in achieving high-precision, robustness, broad reaction coverage and seamless integration into the drug development workflow. To address this, we first constructed the most comprehensive human-specific drug metabolism database to date, encompassing 11,665 human metabolic reactions and 2,497 high-quality rules. Leveraging this resource, we developed ConMeter ( Con trastive learning and feature interaction based Met abolic R eaction prediction), a novel model integrating chemical feature interaction and contrastive learning. ConMeter demonstrates significant improvements, achieving ∼80% accuracy in identifying at least one metabolite within the top 5 predictions and showing an average 25% relative enhancement in ranking true positives compared to state-of-the-art methods. The comprehensive database also expands the range of predictable metabolic reactions. To demonstrate the utility of ConMeter, we integrated it into a metabolite prediction-guided drug design strategy aimed at addressing the low oral bioavailability of a metabolically vulnerable RSK4 lead compound — a pervasive issue among known RSK inhibitors. This strategy successfully yielded R636, a novel RSK4 inhibitor exhibiting remarkably improved bioavailability (a 63-fold increase, reaching 63% absolute bioavailability) while maintaining its potent activity. Notably, R636 showed favorable safety profile and significant anti-tumor efficacy against esophageal squamous cell carcinoma (ESCC) in vitro and in two distinct patient-derived xenograft (PDX) mouse models. This work introduces ConMeter as a powerful and practical tool for high-accuracy metabolite prediction, demonstrating its potential to accelerate lead optimization, exemplified by the discovery of R636 as a promising orally bioavailable candidate for ESCC.


  • Distinct genetic alterations in CD10-negative MUM1-positive follicular lymphoma

    by Yan Yang, Wei Wang, Liang Zhang, Xu Lu, Huihui Li, Yixiong Liu, Zhouyi Xu, Danhui Zhao, Jia Chai, Longfei Shao, et al.